Key result
Calsarcin-1 expression reverses cardiomyocyte hypertrophy and rescues systolic and diastolic dysfunction in preclinical HCM models.
Why the study?
The role of calsarcin-1 in maintaining Z-disc integrity in hypertrophic cardiomyopathy (HCM) remains unclear, and loading conditions to recapitulate pathological mechanical stress in patient-specific iPSC-CM-based engineered heart tissues (EHTs) are underdeveloped.
Does ectopic calsarcin-1 expression restore MLP/Z-disc mechanosensing and rescue pathological hypertrophy and contractile dysfunction in patient-specific and isogenic hypertrophic cardiomyopathy iPSC-derived cardiomyocytes and engineered heart tissues exposed to high afterload?
Does ectopic calsarcin-1 expression restore MLP/Z-disc mechanosensing and rescue pathological hypertrophy and contractile dysfunction in patient-specific and isogenic hypertrophic cardiomyopathy iPSC-derived cardiomyocytes and engineered heart tissues exposed to high afterload?
This preclinical study demonstrates that calsarcin-1 restores MLP/Z-disc mechanosensing and rescues both hypertrophy and high-afterload-induced systolic and diastolic dysfunction in human iPSC-derived engineered heart tissue models of familial hypertrophic cardiomyopathy.
Answers are grounded in this paper and cite their sources.
Should not yet change HCM practice; extends preclinical support for calsarcin-1 in patient-derived models and leaves translation open.
BACKGROUND: Hypertrophic cardiomyopathy (HCM) is an inherited cardiac disease mainly caused by sarcomeric mutations. The Z-disc is a critical mechanosensory interface linking sarcomeric stress to biochemical signaling, yet the role of calsarcin-1 in maintaining Z-disc integrity remains unclear. Patient-specific iPSC-CM-based engineered heart tissues (EHTs) are being developed for disease modeling and drug screening; however, the loading conditions to recapitulate pathological mechanical stress remain underdeveloped. METHODS: HCM patient heart, three patient-specific iPSC lines (MLP-W4R;MYH7-R723C, MYH7-R663H, and MYBPC3-V321M), derived cardiomyocytes (iPSC-CMs), and engineered heart tissues (EHTs) were employed. Calsarcin-1 expression was assessed, and its role in MLP/Z-disc mechanosensing was investigated through gain- and loss-of-function approaches. An EHT bioreactor was developed to recapitulate HCM-associated elevated afterload, electrical pacing, and cyclic mechanical loading; isogenic wild type and MLP-W4R iPSC lines were generated by genome editing. Calsarcin-1 treatment to rescue the hypertrophic phenotype of isogenic (Iso) MLP-W4R iPSC-CM-EHTs was evaluated. RESULTS: Calsarcin-1 was markedly downregulated in myocardium from an HCM proband carrying heterozygous MLP-W4R and MYH7-R723C variants, as well as in patient-specific iPSC-CMs and EHTs, accompanied by marked upregulation of the hypertrophic markers atrial natriuretic factor (ANF) and brain natriuretic peptide (BNP). Ectopic expression of calsarcin-1 via viral infection in MLP-W4R;MYH7-R723C iPSC-CMs stabilized the MLP/Z-disc machinery and reversed hypertrophy in all three patient-specific iPSC-CMs (MLP-W4R;MYH7-R723C, MYH7-R663H, and MYBPC3-V321M). Knockdown of calsarcin-1 attenuated the rescue effect of MLP overexpression in MLP-W4R;MYH7-R723C iPSC-CMs. Isogenic wild type and MLP-W4R iPSCs were generated by correcting mutations in MLP-W4R;MYH7-R723C iPSCs. Moreover, we developed a 3D-EHT bioreactor system that integrates controlled mechanical loading and electrical pacing to recapitulate the elevated afterload and cyclic mechanical stress characteristic of HCM. The additional mechanical resistance imposed by high afterload prolongs TTP and RT50 and increases the normalized force-time integral (nFTI), suggesting that excessively high afterload drives pathological remodeling in IsoMLP-W4R-iPSC-CM-EHTs. More importantly, calsarcin-1 significantly rescued both systolic and diastolic dysfunction of IsoMLP-W4R-iPSC-CM-EHTs exposed to pathological high afterload. CONCLUSIONS: Calsarcin-1 is a nodal regulator of pathological cardiac remodeling that restores MLP/Z-disc mechanosensing. A patient-derived EHT bioreactor model recapitulating pathological HCM loading identifies calsarcin-1 as a potential therapeutic target.
No takes yet. Share an insight, caveat, or question.
Li et al. (2026) studied Familial hypertrophic cardiomyopathy. Calsarcin-1 ectopic expression vs. Untreated or control viral vector / low vs high afterload conditions was evaluated on MLP/Z-disc mechanosensing stability, cardiomyocyte hypertrophy, and systolic/diastolic function (TTP, RT50, nFTI) in EHTs. Calsarcin-1 expression stabilized the MLP/Z-disc complex, reversed hypertrophy in 3 patient-specific iPSC-CM lines, and rescued systolic and diastolic dysfunction in high-afterload HCM EHTs.
Synapse has enriched 10 related papers. Consider them for comparative context: